Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U4 small nuclear 12, pseudogene (RNU4-12P) is annotated as a **pseudogene** and does not produce a functional protein or RNA product[1]. Pseudogenes are segments of DNA that resemble known genes but are typically non-functional due to mutations, lack of regulatory elements, or incomplete sequence. RNU4-12P is classified as a non-coding RNA pseudogene and should not be confused with functional U4 small nuclear RNAs, such as **RNU4-2**, which are essential for spliceosome function and have established roles in neurodevelopmental disease[3][5]. No evidence supports RNU4-12P being a therapeutic target, nor are there known interacting drugs, disease associations, or established roles in biological processes. Its scientific importance is limited to being part of the genomic landscape but not active in cellular or disease pathways[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 12, pseudogene (RNU4-12P).